Intertek announces Dr Jenny Lam as keynote speaker for third Annual Inhaled and Nasal Biologics/DNA Forum 2024

27 Mar 2024

Intertek is pleased to announce that Dr Jenny Lam, Associate Professor in Pharmaceutics at the UCL School of Pharmacy, will be the keynote speaker for the third Annual Inhaled and Nasal Biologics/DNA Forum 2024.

Intertek, a leading Total Quality Assurance provider to industries worldwide, is pleased to announce that Dr Jenny Lam, Associate Professor in Pharmaceutics at the UCL School of Pharmacy, will be the keynote speaker for the third Annual Inhaled and Nasal Biologics/DNA Forum 2024, which will take place from 26-27 September 2024 in Cambridge, UK.

The event, hosted by Intertek, is the industry’s first dedicated forum on inhaled and nasal biologics or DNA medicine development and attracts delegates from around the world. The event provides a platform to share cross-industry understanding on this evolving area of inhaled or nasal drug development, with a common objective of better patient outcomes.

Dr Jenny Lam is a leading expert in novel respiratory delivery systems at the UCL School of Pharmacy, one of the world’s leading pharmacy schools. Dr Lam will present on the theme of ‘Alternative to LNPs – development of peptide-based RNA delivery systems for pulmonary delivery’ (working title), setting the stage for thought-provoking exchanges throughout this groundbreaking industry event.

Dr Lam’s research is focused on the development of novel delivery systems for RNAs and biologics, with a special interest in using particle engineering methods to produce dry powder aerosols for lung delivery, targeting various respiratory diseases and infections. She has published over 90 peer-reviewed articles and filed a number of patent applications on pulmonary drug delivery systems. In 2020, she was awarded the DDL Emerging Scientist Award which recognised her significant accomplishment and innovation in inhalation science. Additionally, Dr Lam recently co-edited ‘Respiratory Delivery of Biologics, Nucleic Acids and Vaccines’, a comprehensive review of pulmonary delivery of macromolecules and biologics.

Hosting this annual forum highlights Intertek’s commitment to supporting the advance of science, regulatory frameworks, and innovation in the field of inhaled and nasal biologics or DNA therapeutic or vaccine development. With a Centre of Excellence for the development of these products at its Cambridge, UK, campus, Intertek supports clients around the world to meet milestones for their challenging pharmaceutical development programmes.

Chris Vernall, Intertek Commercial Director, commented: “We are truly excited to welcome Dr Jenny Lam as keynote speaker for the third edition of the Annual Inhaled and Nasal Biologics/DNA Forum 2024. Dr Lam’s extensive experience in the area of formulation and delivery of macromolecules will be immensely insightful for anyone involved in this complex area of drug development. We are sure Dr Lam’s talk will be a highlight of this must-attend event for professionals, thought leaders, and stakeholders in the field. With a dynamic lineup of speakers, interactive sessions, and networking opportunities, the conference provides a platform for collaboration, learning, and innovation.”

Dr Lam added: “I look forward to joining fellow researchers and innovators in inhaled biologic and nucleic acid therapeutics development at the upcoming conference in Cambridge and delivering the keynote on the topic of novel systems for pulmonary delivery. The synergy fostered by gatherings like this propels us forward, offering fertile ground for interdisciplinary collaborations to flourish."

Registration is now open, and early bird discounts are available until 31 May 2024. For more information, visit the conference website today.

#

For Media Information

Please contact:
Lorna Kettle
ECA Marketing Director, Intertek Pharmaceutical Services
T: +44 (0) 116 296 1620
E: lorna.kettle@intertek.com

About Intertek Pharmaceutical Services

 Intertek’s pharmaceutical services locations include Melbourn, Cambridge (UK), Manchester (UK), Basel (Switzerland), Whitehouse, (New Jersey, USA), Mumbai (India) and Melbourne, (Australia).

About Intertek

TOTAL QUALITY. ASSURED.
Intertek is a leading Total Quality Assurance provider to industries worldwide. Our network of more than 1,000 laboratories in more than 100 countries, delivers innovative and bespoke Assurance, Testing, Inspection and Certification solutions for our customers’ operations and supply chains. Intertek Total Quality Assurance expertise, delivered consistently with precision, pace and passion, enabling our customers to power ahead safely.

intertek.com